Here is the only clinical data: https://ascopubs.org/doi/abs/10.1200/JCO.2020.38.15_suppl.4632 https://ascopubs.org/doi/abs/10.1200/JCO.2020.38.15_suppl.46...

Here is the only clinical data: https://ascopubs.org/doi/abs/10.1200/JCO.2020.38.15_suppl.4632 https://ascopubs.org/doi/abs/10.1200/JCO.2020.38.15_suppl.46... Looks as promising as any other promising cancer therapy in phase I trials! There is a renaissance in cancer drug delivery at present, exemplified by antibody drug conjugates. The tech in the article is very interesting, and a superb bioengineering effort. A caveat is that complex multi-unit therapies don’t have a great track record. They are hard to manufacture reliably, and have a very large optimisation volume, so it’s difficult to increment the development as you only have finite resources for human trials. Contrast this with small molecules where there is a well defined process over various chemical and pharmacokinetic factors, prior to testing in humans. We also lack a good system for developing and trialing ‘platform’ tech like this - the current system is set up for single drugs/combos to be tested and eventually reimbursed in each cancer type separately. If you have a platform for delivering tailored therapies agnostic of cancer type, you will run into many barriers. There is currently only one drug I know of simultaneously approved across multiple cancer types (pembrolizumab in mismatch repair deficient tumours, a rare population). So many challenges ahead of the hype here.